The global intramedullary osteosarcoma treatment market is poised for substantial growth, projected to reach USD 920.3 million by 2033 from USD 489.86 million in 2022, with a steady compound annual growth rate (CAGR) of 4.9% from 2023 to 2033. Intramedullary osteosarcoma, the most prevalent form of bone cancer, primarily affects the cells responsible for bone …